Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients
- 25 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Abdominal Radiology
- Vol. 38 (2), 265-272
- https://doi.org/10.1007/s00261-012-9913-3
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Bevacizumab in association with de Gramont 5‐fluorouracil/folinic acid in patients with oxaliplatin‐, irinotecan‐, and cetuximab‐refractory colorectal cancerCancer, 2009
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnnals Of Oncology, 2009
- Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case reportAmerican Journal of Obstetrics and Gynecology, 2009
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II ConsortiaJournal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Management of bevacizumab-associated bowel perforation: a case series and review of the literatureAnnals Of Oncology, 2007
- Delayed Rectovaginal Fistula: A Potential Complication of Bevacizumab (Avastin)Diseases of the Colon & Rectum, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Managing Patients Treated with Bevacizumab Combination TherapyOncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004